There is a pressing need to optimize medication strategies in older adults with cancer, many of whom take ≥5 medications. A randomized controlled trial published in the Journal of Internal Medicine demonstrated that an advisory letter containing the results of a pharmacist-led comprehensive medication review sent to physicians can decrease common medication problems among older cancer patients during rehabilitation.
Overall, 443 participants aged ≥65 years who use ≥5 drugs regularly were included. At the end of the trial, fewer patients in the medication review group had potentially inappropriate prescriptions compared with patients in the usual care group (29.9% versus 70.8%). Likewise, there was less medication overuse (34.2% versus 64.1%) and medication underuse (44.9% versus 73.2%). Furthermore, 337 missing vaccinations (against influenza, pneumonia, COVID-19, and/or shingles) were recommended in the medication review group.
“The pharmacist-led comprehensive medication review to counsel physicians in oncological rehabilitation wards was highly feasible and substantially improved the medication quality of older cancer patients with polypharmacy,” said corresponding author Ben Schöttker, PhD, of the German Cancer Research Center.
URL upon publication: https://onlinelibrary.wiley.com/doi/10.1111/joim.70161
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com .
About the Journal
Journal of Internal Medicine is a peer-reviewed scientific journal that publishes original clinical work from bench to bedside covering a broad field of its subspecialties. JIM features original articles, reviews and clinical updates.
About Wiley
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com . Follow us on Facebook , X , LinkedIn and Instagram .
Journal of Internal Medicine
Cancer co-medication quality in older patients with polypharmacy: a large randomized trial testing a medication review versus usual care
23-Sep-2026